Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

NCT ID: NCT01783639

Last Updated: 2017-08-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2015-04-30

Brief Summary

The purpose of this study is to compare the safety and performance of WIRION™ EPD in patients undergoing carotid artery stenting to a performance goal based on an analysis of the results of previous US IDE carotid stenting with embolic protection studies

Detailed Description

Patient registry procedures include:

• Clinical Events Committee (CEC); responsibility for validating all reported primary safety outcomes
• Data Safety Monitoring Board (DSMB); to review and evaluate safety data including serious adverse events
• 100% data monitoring; to compare data entered into the registry
• Source data verification; to assess the accuracy, completeness of registry data by comparing the data to external data sources (e.g., medical records, paper or electronic case report forms).
• Standard Operating Procedures; to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis and reporting for adverse events.
• Sample size assessment to specify the number of participants and follow up duration.
• Data Management Plan; to address situations where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results
• Statistical analysis plan; describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.

Conditions

Carotid Artery Diseases; Stroke

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Arm 1

Device: WIRION™ Embolic Protection System

Interventions: Carotid Artery Stent

Group Type: EXPERIMENTAL

Carotid Artery Stent

Intervention Type: PROCEDURE

Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices

Interventions

Carotid Artery Stent

Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• 18 years of age
• Anticipated patient life expectancy of at least 1 year
• Patient or authorized representative, signed a written Informed Consent form
• Patient is willing to comply with the protocol requirements
• Candidate for catheter-based therapy of a single stenosis located in the internal carotid artery (ICA) or the carotid bifurcation, suitable for treatment with a single FDA-approved stent with a carotid use indication
• Reference vessel diameter for intended filter location between 3.5mm and 6.0mm
• An adequate "landing zone" of at least 30mm
• Patients with severe symptomatic or asymptomatic carotid artery stenosis, to be ≥ 50% for symptomatic patients OR ≥ 80% for asymptomatic patients
• At least one high surgical risk criteria, either anatomical or co-morbid risk factors, as listed below:

Category I - Anatomical high risk factors

• Recurrent stenosis after endarterectomy
• Previous radical neck surgery or radiation therapy to the neck
• High cervical ICA lesions or CCA lesions at or above C2 or below the clavicle
• Spinal immobility of the neck
• Tracheostomy or tracheal stoma
• Any laryngeal nerve palsy and bilateral carotid artery stenosis

Category II - Co-morbid risk factors

• Contralateral carotid occlusion
• Unstable angina (Canadian Cardiovascular Society class III/IV)
• Congestive Heart Failure (New York Heart Association functional class III/IV) and/or known severe left ventricular dysfunction LVEF<30%
• Requires coronary artery bypass surgery, cardiac valve surgery, major vascular surgery, or abdominal aortic aneurysm repair 31-60 days post carotid stent procedure
• Recent MI (>72 hr and <4 weeks)
• Severe pulmonary disease with FEV1 of <30%
• CAD in ≥2 unrevascularized vessels with stenosis ≥70%
• Age ≥75 years
• Uncontrolled diabetes - Female patient with no child bearing potential or has negative pregnancy test within the previous 7 days and agrees to remain on birth control throughout the study

Exclusion Criteria

• Total occlusion or near-occlusion of the target vessel
• Severe lesion calcification
• Presence of an alternate source of emboli
• Presence of a filling defect, or angiographically visible thrombus, at target site
• A greater than 50% CCA lesion proximal to the target or a distal (intracranial) lesion more severe than the target lesion
• Evolving, acute or recent stroke within the last 30 days
• Major stroke with a residual neurological deficit that would confound neurologic assessment
• Vertebrobasilar insufficiency symptoms only
• Major operation 30 days before or after the index procedure
• Ipsilateral intracranial stenosis that requires treatment
• Any pre-existing stent in ipsilateral carotid artery, or placement of a stent in contralateral carotid within 30 days of the index procedure
• History of intracranial hemorrhage within 12 months
• Any condition that precludes proper angiographic assessment or prevents femoral arterial access
• Uncontrolled hypertension
• Contraindication to heparin and bivalirudin, aspirin, thienopyridines
• Known sensitivity to radiographic contrast media which cannot be controlled with pre-medication
• History or current indication of bleeding diathesis or coagulopathy
• Chronic renal insufficiency
• Carotid artery dissection or aortic arch anatomical anomalies
• Dementia or a neurological illness
• Patient is enrolled in another drug or device study protocol that has not reached its primary endpoint
• Severe pulmonary hypertension
• Intra-cranial pathology (e.g., tumor, AVM. aneurysm, etc) that would make study participation inappropriate or confound neurologic assessment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Gardia Medical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dierk Scheinert, MD

Role: PRINCIPAL_INVESTIGATOR

Herzzentrum Leipzig GmbH and Park-Krankenhaus Leipzig

Horst Sievert, MD

Role: PRINCIPAL_INVESTIGATOR

Cardio Vascular Center Frankfurt

Stefan Rohde, MD

Role: PRINCIPAL_INVESTIGATOR

Radiologische Klinik, Klinikum Dortmund GmbH

Joachim Schofer, MD

Role: PRINCIPAL_INVESTIGATOR

Universitäres Herz- und Gefäßzentrum Hamburg

Harald Mudra, MD

Role: PRINCIPAL_INVESTIGATOR

Städtisches Klinikum München GmbH

Marc Bosiers, MD

Role: PRINCIPAL_INVESTIGATOR

AZ St-Blasius, Dendermonde

Thomas Zeller, MD

Role: PRINCIPAL_INVESTIGATOR

Universitaets Herzzentrum, Bad-Krozingen

Alberto Cremonesi, MD

Role: PRINCIPAL_INVESTIGATOR

Villa Maria Cecilia, Contignola

Bernhard Reimers, MD

Role: PRINCIPAL_INVESTIGATOR

Mirano Hospital

Henrik Schröder, MD

Role: PRINCIPAL_INVESTIGATOR

Ihre-Radiologen.de

Locations

AZ Sint Blasius Hospital, Department of Vascular Surgery

Dendermonde, , Belgium

Universitaets Herzzentrum

Bad Krozingen, , Germany

Ihre-Radiologen.de

Berlin, , Germany

Klinikum Dortmund GmbH

Dortmund, , Germany

CardioVascular Center Frankfurt

Frankfurt, , Germany

Hamburg University Cardiovascular Center

Hamburg, , Germany

Herzzentrum and Park-Krankenhaus

Leipzig, , Germany

Städtisches Klinikum München GmbH Klinikum Neuperlach

Munich, , Germany

Villa Maria Cecilia Hospital

Cotignola, , Italy

Mirano Hospital

Mirano, , Italy

Countries

Belgium; Germany; Italy

References

Scheinert D, Reimers B, Cremonesi A, Schmidt A, Sievert H, Rohde S, Schofer J, Mudra HG, Bosiers M, Zeller T, Pacchioni A, Rosenschein U; WISE (Wirion Study Europe) Pivotal Trial Investigators. Independent Modular Filter for Embolic Protection in Carotid Stenting. Circ Cardiovasc Interv. 2017 Mar;10(3):e004244. doi: 10.1161/CIRCINTERVENTIONS.116.004244.

Reference Type: DERIVED

PMID: 28283511 (View on PubMed)

Other Identifiers

WIRION Study Europe (WISE)

Identifier Type: OTHER

Identifier Source: secondary_id

WIRION™ Pivotal Study (WISE)

Identifier Type: -

Identifier Source: org_study_id